Lung Cancer


This is a Phase III double-blind, placebo-controlled study of Durvalumab versus Placebo in patients with stage II-III NSCLC who are MRD-positive following curative intent therapy.

Trial overview


Carcinoma, non-small cell lung

Eligibility criteria

  • Early Stage Non-Small Cell Lung Cancer requiring surgery
  • No known mutations in the lung cancer
  • Completion of adjuvant chemotherapy, or no chemotherapy

Study details

This study requires tumour tissue and blood tests close to the date of the lung cancer surgery. This assessment determines the eligibility for the trial.

There is close follow up with blood tests after completion of intial chemotherapy. If eligible for the trial the patient is randomised to durvalumab or placebo.

While on treatment there will be regular blood tests and scans to monitor progress. At completion of treatment the study will continue to follow your progress.

Further information

For more information regarding this clinical trial click here.


Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.